• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Researc

  2026-07-06

  Masitinib (AB1010) is a highly selective tyrosine kinase inhibitor for targeted inhibition of KIT, PDGFRα, and PDGFRβ in preclinical cancer, mastocytosis, and inflammatory disease research. It is optimized for DMSO-based protocols and is not appropriate in workflows requiring water or ethanol solubility, or broad-spectrum kinase inhibition.

• Doxorubicin in Research: Overcoming ABCG2-Mediated Resistanc

  2026-07-06

  Explore the advanced scientific mechanisms of Doxorubicin, also known as Adriamycin, with a focus on overcoming multidrug resistance in cancer research. This article offers a unique perspective on assay optimization and resistance modulation, grounded in the latest transporter research.

• Applied Use of Z-WEHD-FMK in Inflammation and Pyroptosis Ass

  2026-07-05

  Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) enables precise and irreversible inhibition of inflammatory caspases, empowering researchers to dissect caspase-driven signaling in cell biology and infectious disease models. This article translates recent mechanistic insights into actionable workflows, troubleshooting guidance, and comparative advantages for advanced inflammation research.

• ATF4 Attenuates Doxorubicin-Induced Cardiotoxicity via H2S P

  2026-07-04

  This study demonstrates that ATF4 protects against doxorubicin-induced cardiomyopathy by enhancing hydrogen sulfide-mediated antioxidation, revealing a novel transcriptional mechanism involving CSE upregulation. These findings highlight ATF4 as a potential therapeutic target for mitigating the cardiotoxic effects of anthracycline chemotherapy in translational research models.

• Ibrexafungerp and Caspofungin in Treating Resistant Candida

  2026-07-03

  Wiederhold et al. demonstrate that ibrexafungerp, a first-in-class triterpenoid, exhibits potent in vitro and in vivo activity against fluconazole-resistant Candida auris, even with delayed therapy initiation. Their study benchmarks caspofungin as a comparator, reinforcing the clinical and research relevance of targeting β-(1,3)-D-glucan biosynthesis in antifungal strategies.

• Universal nPEC Method Optimizes Dual-Loaded Liposome Efficie

  2026-07-03

  This study introduces a robust nanoparticle exclusion chromatography (nPEC) method for accurately determining the encapsulation efficiency of both hydrophilic and lipophilic drugs in dual-loaded liposomes. The work addresses a key analytical challenge in combinatorial drug delivery, enabling reproducible and universally applicable assessments crucial for advanced therapeutic research.

• Caspofungin: Strategic Antifungal Innovation for Translation

  2026-07-02

  This thought-leadership article explores the mechanistic and translational power of Caspofungin, a lipopeptide antifungal drug, for research teams confronting azole-resistant Candida infections. By blending biological insight with protocol-driven guidance and evidence-backed context, it charts a path for investigators to optimize antifungal strategies and drive discovery in the evolving landscape of fungal therapeutics.

• Valemetostat (DS-3201): Transforming EZH2 Mutant Lymphoma Re

  2026-07-02

  This thought-leadership article explores the mechanistic and translational impact of Valemetostat (DS-3201), a first-in-class dual inhibitor targeting EZH1 and EZH2, on relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. Bridging mechanistic insights, experimental guidance, and strategic context, it positions Valemetostat as a pivotal tool for advancing epigenetic cancer therapy, while differentiating its discussion from standard product reviews.

• Aclacinomycin A: Mechanistic Insights and rDNA Damage Paradi

  2026-07-01

  Explore how Aclacinomycin A (Aclarubicin) uniquely disrupts ribosomal DNA integrity via topological stress, illuminating new assay strategies for apoptosis and genome stability. This article delivers in-depth mechanistic analysis and practical guidance distinct from prior workflows.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina

  2026-07-01

  This study identifies Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) as a potent ferroptosis inducer in triple-negative breast cancer (TNBC), acting through CUL3-mediated ubiquitination of MTDH. The findings establish a novel mechanistic pathway for ferroptosis regulation and highlight Gramine's translational potential in cancer biology research.

• Chlorin e6 Photosensitizer: Protocols for Advanced PDT Resea

  2026-06-30

  Chlorin e6 (Ce6) empowers both cancer therapy and antibacterial wound care with potent, light-triggered reactive oxygen species generation. Discover applied workflows, troubleshooting, and novel protocols—anchored by the latest innovation in silk fibroin nanofiber films and supported by APExBIO’s high-quality Ce6.

• Salinomycin: Polyether Ionophore Antibiotic for Advanced HCC

  2026-06-30

  Salinomycin stands out as a polyether ionophore antibiotic uniquely suited for hepatocellular carcinoma research, targeting cancer stem-like cells through Wnt/β-catenin pathway inhibition and apoptosis induction. Its robust activity profile and well-characterized mechanism make it a gold standard for mechanistic studies and drug response workflows.

• Oral CXCR4 Antagonist Mavorixafor in WHIM Syndrome: Phase 3

  2026-06-29

  Badolato et al.'s placebo-controlled phase 3 trial establishes the clinical utility of mavorixafor, a selective CXCR4 antagonist, for WHIM syndrome. The study demonstrates significant improvements in neutrophil and lymphocyte counts and a marked reduction in infection rates, highlighting a new therapeutic era for this rare immunodeficiency.

• MnTBAP Chloride (SKU B5964): Reliable SOD Mimetic for Oxidat

  2026-06-29

  This article guides biomedical researchers through real laboratory challenges in redox biology, focusing on how MnTBAP Chloride (SKU B5964) delivers reproducible oxidative stress modulation and neuroinflammation control. Using scenario-driven Q&A, it translates literature and workflow data into actionable protocols—helping labs optimize cell-based and animal experiments with confidence in compound quality, cost, and performance.

• DOT1L Inhibition Enhances Lenalidomide Response in Myeloma

  2026-06-28

  The referenced study demonstrates that DOT1L inhibition activates innate immune signaling, thereby potentiating the anti-myeloma effects of lenalidomide (CC-5013). These findings clarify a critical epigenetic-immune synergy and provide a mechanistic foundation for combination strategies in multiple myeloma research.

15748 records 1/1050 page Next 12345 下5页 Last page